NIH | National Cancer Institute | NCI Wiki  

  • Created by Unknown User (brennanrm), last modified by Unknown User (wileyal) on Jul 11, 2012
  • Enzmann DR (2012) Radiology’s Value Chain. Radiology 263(1):243-252.
  • Gorovets D, et al. (2012) IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower-Grade Diffuse Astrocytic Glioma. Clinical Cancer Research.
  • Adam SA, et al. (2012) ALDH1A1 is a marker of astrocytic differentiation during brain development and correlates with better survival in glioblastoma patients. Brain Pathology.
  • Patlak M, Balogh E, & Nass S (2012) Facilitating Collaborations to Develop Combination Investigational Cancer Therapies. National Cancer Policy Forum.
  • Turcan S, et al. (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature advance online publication.
  • Cork SM, et al. (2012) A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40[[thinsp]]kDa vasculostatin from tumor suppressor BAI1. Oncogene.
  • Gyorffy B, Lanczky A, & Szallasi Z (2012) Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocrine-Related Cancer.
  • Amlin-Van Schaick JC, et al. (2012) Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12. Neuro-Oncology.
  • Wenlong T, et al. (2011) Classifying six glioma subtypes from combined gene expression and CNVs data based on compressive sensing approach. Bioinformatics and Biomedicine Workshops (BIBMW), 2011 IEEE International Conference on, pp 282-288.
  • Tang W, et al. (2011) Classifying six glioma subtypes from combined gene expression and CNVs data based on compressive sensing approach. Bioinformatics and Biomedicine Workshops (BIBMW), 2011 IEEE International Conference on, pp 282-288.
  • Esserman L, et al. (Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment:1-14.
  • Augustin I, et al. (2011) The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Molecular Medicine:n/a-n/a.
  • Kong J, et al. (2011) Nuclear Morphometry Analysis with Whole-Slide Microscopy Images of Low-grade Glioma. ACM Conference on Bioinformatics, Computational Biology and Biomedicine Conference 2011.
  • Ambrose LF, Freedman J, Buetow K, Friend S, & Schilsky RL (2011) Using Patient-Initiated Study Participation in the Development of Evidence for Personalized Cancer Therapy. Clinical Cancer Research 17(21):6651-6657.
  • Sin W-C, Crespin S, & Mesnil M (2011) Opposing roles of connexin43 in glioma progression. Biochimica et Biophysica Acta (BBA) - Biomembranes (0).
  • Hu H, et al. (2011) DW4TR: A Data Warehouse for Translational Research. Journal of Biomedical Informatics (0).
  • Wang M, et al. (2011) BTECH: A Platform to Integrate Genomic, Transcriptomic and Epigenomic Alterations in Brain Tumors. Neuroinformatics 9(1):59-67.
  • Smith M, Harbach M, Mertins S, Lewis A, & Griffiths L (2011) Towards a translational medical research ecosystem. Digital Ecosystems and Technologies Conference (DEST), 2011 Proceedings of the 5th IEEE International Conference on, pp 120-126.
  • Levy MA & Rubin DL (2011) Computational approaches to assist in the evaluation of cancer treatment response. Imaging in Medicine 3(2):233-246.
  • Barnholtz-Sloan J & Chance M (2011) Frontiers of Oncology: Biobanking Resources for the 21st Century. Journal of Clinical Bioinformatics 1(1):13.
  • Yong M & Begent R (2010) Best use of experimental data in cancer informatics. Future Oncology 6(10):1551-1562.
  • Kurc T, et al. (2010) Middleware Architecture Approaches for Collaborative Cancer Research. Biomedical Informatics for Cancer Research, eds Ochs MF, Casagrande JT, & Davuluri RV (Springer US), pp 73-90.
  • Beck JR (2010) The Cancer Biomedical Informatics Grid (caBIG (TM) ): An Evolving Community for Cancer Research. Biomedical Informatics for Cancer Research, eds Ochs MF, Casagrande JT, & Davuluri RV (Springer US), pp 177-200.
  • Kenneth H B (2009) An infrastructure for interconnecting research institutions. Drug Discovery Today 14(11-12):605-610.
  • Buetow KH (2009) Enabling personalized medicine through an interoperable IT infrastructure: an overview of the cancer Biomedical Informatics Grid (R). Personalized Medicine 6(4):439-448.
  • Walker L, et al. (2008) Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA mutation carriers. Breast Cancer Research and Treatment 112(2):229-236.
  • McConnell P, et al. (2008) The cancer translational research informatics platform. BMC Medical Informatics and Decision Making 8(1):60.
  • Frey LJ, Maojo V, & Mitchell JA (2007) Bioinformatics linkage of heterogeneous clinical and genomic information in support of personalized medicine. (Translated from eng) Yearb Med Inform:98-105 (in eng).
  • Adam S K (Genome-wide association study of prostate cancer identifies a second risk locus at 8q24: Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF, Hoover R, Hunter DJ, Chanock SJ, Thomas G, SAIC-Frederick, National Cancer Institute (NCI)-Frederick Cancer Research and Development Center, Frederick, MD; and Division of Cancer Epidemiology and Genetics, Center for Cancer Research, NCI, U.S. National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Bethesda, MD. Urologic Oncology: Seminars and Original Investigations 25(5):447-448.
  • Merk BC, Owens JL, Lopes MB, Silva CM, & Hussaini IM (2011) STAT6 expression in glioblastoma promotes invasive growth. (Translated from eng) BMC Cancer 11:184 (in eng).
  • Song H-R, et al. (2010) Nuclear factor IA is expressed in astrocytomas and is associated with improved survival. Neuro-Oncology 12(2):122-132.
  • Smits M, et al. (2010) miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. (Translated from eng) Oncotarget 1(8):710-720 (in eng).
  • Cooper LAD, et al. (2010) The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas. Plos One 5(9):e12548.
  • Cao Y, et al. (2010) Erythropoietin Receptor Signaling through STAT3 Is Required for Glioma Stem Cell Maintenance. Genes & Cancer 1(1):50-61.
  • Madhavan S, et al. (2009) Rembrandt: Helping Personalized Medicine Become a Reality through Integrative Translational Research. Molecular Cancer Research 7(2):157-167.
  • Li Z, et al. (2009) Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells. Cancer Cell 15(6):501-513.
  • Guo AM, et al. (2008) Expression of CYP4A1 in U251 Human Glioma Cell Induces Hyperproliferative Phenotype in Vitro and Rapidly Growing Tumors in Vivo. Journal of Pharmacology and Experimental Therapeutics 327(1):10-19.
  • Holick CN, et al. (2007) Comprehensive Association Analysis of the Vitamin D Pathway Genes, VDR, CYP27B1, and CYP24A1, in Prostate Cancer. Cancer Epidemiology Biomarkers & Prevention 16(10):1990-1999.
  • Natsume A, et al. (2011) Girdin maintains the stemness of glioblastoma stem cells. Oncogene.
  • No labels